Skip to main content

Advertisement

Table 1 Correlations between staining of Foxc2, E-cadherin and clinicophathologic characteristics in 309 NSCLC patients

From: Prognostic value of high FoxC2 expression in resectable non-small cell lung cancer, alone or in combination with E-cadherin expression

Variables Foxc2-L Foxc2-H p E-cadherin-I E-cadherin-P p
n = 227 n = 82 n = 127 n = 182
Age       
  ≤ 65 89 26 0.062 45 70 0.551
  > 65 138 56   82 112  
Sex       
 Male 154 55 0.891 90 119 0.329
 Female 73 27   37 63  
Tobacco use       
 No 117 35 0.047 59 93 0.223
 Yes 110 47   68 89  
Pathological type       
 Adenocarcinoma 131 58 0.008b 77 112 0.653b
 Squamous cell carcinoma 76 13   40 49  
 Othera 20 11   10 21  
TNM stage       
 I 45 17 0.679 22 40 0.432
 II–III 182 65   105 142  
pT status       
 T1 57 18 0.549 33 42 0.516
 T2-4 170 64   94 140  
pN status       
 N0 79 12 < 0.001 30 61 0.041
 N1-2 148 70   97 121  
Pleural involvement       
 No 181 68 0.372 98 151 0.245
 Yes 46 14   29 31  
Differentiation       
 Well/moderate 85 33 0.606 45 73 0.338
 Poor 142 49   82 109  
Vascular invasion       
 No 200 71 0.617 109 162 0.568
 Yes 27 11   18 20  
  1. FoxC2-H high expression of FoxC2; FoxC2-L low expression of FoxC2
  2. E-cadherin-I impaired expression of E-cadherin; E-cadherin-P preserved expression of E-cadherin
  3. a Other including adenosquamous carcinoma, mucoepidermoid carcinoma, carcinosarcoma, large-cell carcinoma, and atypical carcinoid
  4. b p value was analyzed by Adenocarcinoma vs. non- Adenocarcinoma using the chi-square test